EVOGENE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.68 USD | -3.00% |
|
-11.24% | -19.05% |
| 05-23 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
| 05-23 | Evogene Ltd. Provides Revenue Guidance for the Year 2024 | CI |
| Sales 2024 * | 17M 23.26M | Sales 2025 * | 31.5M 43.1M | Capitalization | 34.36M 47.02M |
|---|---|---|---|---|---|
| Net income 2024 * | -20M -27.37M | Net income 2025 * | -17M -23.26M | EV / Sales 2024 * | 2.02 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.09 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 142 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evogene Ltd.
More press releases
| 1 day | -3.00% | ||
| 1 week | -11.24% | ||
| Current month | -8.72% | ||
| 1 month | -4.70% | ||
| 3 months | -26.77% | ||
| 6 months | -19.06% | ||
| Current year | -19.05% |
1 week
0.67
0.76
1 month
0.640.90
Current year
0.611.04
1 year
0.451.44
3 years
0.454.10
5 years
0.4510.24
10 years
0.4516.82
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 0.68 | -3.00% | 47,238 |
| 24-06-05 | 0.701 | -4.90% | 106,438 |
| 24-06-04 | 0.7371 | -1.71% | 87,101 |
| 24-06-03 | 0.7499 | +0.66% | 30,875 |
| 24-05-31 | 0.745 | -2.75% | 34,748 |
Delayed Quote Nasdaq, June 06, 2024 at 03:59 pm
More quotes
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +55.55% | 59.28B | |
| +43.34% | 40.94B | |
| -4.71% | 40.17B | |
| -5.56% | 28.69B | |
| +13.76% | 26.63B | |
| -22.00% | 18.89B | |
| +31.50% | 12.46B | |
| +2.16% | 12.42B | |
| +25.70% | 12.26B |
- Stock Market
- Equities
- EVGN Stock
- EVGN Stock
